Curated News
By: NewsRamp Editorial Staff
September 17, 2025
Creative Biolabs Launches Advanced Neuroscience Tools for Alzheimer's Research
TLDR
- Creative Biolabs' new neuroscience tools provide researchers with advanced competitive advantages in drug screening and Alzheimer's disease model development.
- Creative Biolabs developed specialized assays using live-cell imaging and co-culture systems to study Schwann cell function and microglial phagocytosis mechanisms.
- These neuroscience platforms advance Alzheimer's research, potentially leading to better treatments for the 55 million people worldwide living with dementia.
- Creative Biolabs offers real-time visualization of microglial phagocytosis and a webinar on microglia's role in Alzheimer's disease tomorrow.
Impact - Why it Matters
This development matters significantly because neurodegenerative diseases like Alzheimer's affect millions globally and represent one of the most challenging healthcare crises of our time. The tools and services introduced by Creative Biolabs accelerate research into disease mechanisms and potential treatments, potentially shortening the timeline for developing effective therapies. For patients and families affected by these devastating conditions, advancements in research tools mean hope for better treatments and ultimately cures. The ability to study both peripheral and central nervous system functions with greater precision could lead to breakthroughs in understanding disease progression and identifying novel therapeutic targets.
Summary
Creative Biolabs, a leading biotechnology company specializing in neuroscience research, has launched innovative translational neuroscience tools to address the growing global challenge of neurodegenerative diseases like Alzheimer's. With the World Health Organization reporting over 55 million people worldwide living with dementia, the company has developed specialized platforms focusing on both peripheral and central nervous system mechanisms. Their comprehensive Schwann Cell Assay platform enables isolation of Schwann cells from human, mouse, and rat species, supporting co-culture systems with neurons to assess critical functional measures including neurotrophic factor secretion and myelination potential.
The company has also introduced its microglia phagocytosis assay service, utilizing live-cell imaging and fluorescently labeled bioparticles to visualize microglial phagocytic function in real time. Additionally, Creative Biolabs has developed advanced preclinical assessment services for Alzheimer's disease models, creating both 2D and 3D platforms that replicate key disease aspects including amyloid deposition, tauopathy, and neuroinflammation. These models, derived from patient-induced pluripotent stem cells, provide robust contexts for drug screening and mechanistic studies. The company is further supporting research through an upcoming webinar on microglia's role in Alzheimer's disease, scheduled for September 18, 2025.
Source Statement
This curated news summary relied on content disributed by 24-7 Press Release. Read the original source here, Creative Biolabs Launches Advanced Neuroscience Tools for Alzheimer's Research
